483 related articles for article (PubMed ID: 18294265)
1. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
Yazisiz V; Avci AB; Erbasan F; Yildirim B; Terzioğlu E
Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265
[TBL] [Abstract][Full Text] [Related]
2. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action.
Haraoui B; Krelenbaum M
Semin Arthritis Rheum; 2009 Dec; 39(3):176-81. PubMed ID: 18706681
[TBL] [Abstract][Full Text] [Related]
3. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
[TBL] [Abstract][Full Text] [Related]
4. [Anti-TNF alfa therapy in ankylosing spondylitis].
Cravo AR; Tavares V; Da Silva JC
Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
[TBL] [Abstract][Full Text] [Related]
5. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J
Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540
[TBL] [Abstract][Full Text] [Related]
6. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
7. New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.
Song IH; Appel H; Haibel H; Loddenkemper C; Braun J; Sieper J; Rudwaleit M
J Rheumatol; 2008 Mar; 35(3):532-6. PubMed ID: 18203308
[TBL] [Abstract][Full Text] [Related]
8. [Anti-TNF-alpha treatment and spondyloarthropathies].
Braun Y; Balbir-Gurman A
Harefuah; 2002 Nov; 141(11):965-8, 1010. PubMed ID: 12476631
[TBL] [Abstract][Full Text] [Related]
9. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
Toussirot É; Houvenagel É; Goëb V; Fouache D; Martin A; Le Dantec P; Dernis E; Wendling D; Ansemant T; Berthelot JM; Bader-Meunier B; Kantelip B;
Joint Bone Spine; 2012 Oct; 79(5):457-63. PubMed ID: 22088934
[TBL] [Abstract][Full Text] [Related]
10. Infliximab induced T lymphocyte apoptosis in Crohn's disease.
van den Brande J; Hommes DW; Peppelenbosch MP
J Rheumatol Suppl; 2005 Mar; 74():26-30. PubMed ID: 15742461
[TBL] [Abstract][Full Text] [Related]
11. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
Kakkassery V; Mergler S; Pleyer U
Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052
[TBL] [Abstract][Full Text] [Related]
12. Diverse effects of infliximab and etanercept on T lymphocytes.
Sieper J; Van Den Brande J
Semin Arthritis Rheum; 2005 Apr; 34(5 Suppl1):23-7. PubMed ID: 15852251
[TBL] [Abstract][Full Text] [Related]
13. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases.
Famenini S; Wu JJ
J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169
[TBL] [Abstract][Full Text] [Related]
14. Anti-TNF-alpha therapy in ankylosing spondylitis.
De Keyser F; Van den Bosch F; Mielants H
Cytokine; 2006 Mar; 33(5):294-8. PubMed ID: 16516484
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
[TBL] [Abstract][Full Text] [Related]
16. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
[TBL] [Abstract][Full Text] [Related]
17. Tumour necrosis factor inhibitors in ankylosing spondylitis.
Reed MR; Taylor AL
Intern Med J; 2008 Oct; 38(10):781-9. PubMed ID: 18422565
[TBL] [Abstract][Full Text] [Related]
18. [Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept].
Breedveld FC
Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2273-7. PubMed ID: 16240851
[TBL] [Abstract][Full Text] [Related]
19. [Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis].
Pontikaki I; Gerloni V; Gattinara M; Luriati A; Salmaso A; De Marco G; Teruzzi B; Valcamonica E; Fantini F
Reumatismo; 2006; 58(1):31-8. PubMed ID: 16639486
[TBL] [Abstract][Full Text] [Related]
20. Both etanercept and infliximab can elevate tumor necrosis factor (TNF)-alpha and be the cause of treatment related new onset disease: the need to measure circulating TNF-alpha.
Kast RE; Altschuler EL
J Rheumatol; 2008 Aug; 35(8):1679; author reply 1679-80. PubMed ID: 18671327
[No Abstract] [Full Text] [Related]
[Next] [New Search]
